e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improvement of exercise capacity due to beta blocker treatment in the model of MCT induced pulmonary hypertension
S. Schroll, T. Lange, M. Arzt, D. Sebah, B. Stoelcker, M. Pfeifer (Regensburg, Donaustauf, Germany)
Source:
Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Session:
Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Session type:
Thematic Poster Session
Number:
1065
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Schroll, T. Lange, M. Arzt, D. Sebah, B. Stoelcker, M. Pfeifer (Regensburg, Donaustauf, Germany). Improvement of exercise capacity due to beta blocker treatment in the model of MCT induced pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 1065
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Experimental hypoxia-induced pulmonary hypertension is prevented by moderate exercise training in mice
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Effect of treatment on exercise endurance tolerance and ventilatory efficiency in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Voluntary exercise increases survival and exercise capacity in a monocrotaline-induced pulmonary hypertension in rats
Source: International Congress 2018 – Cardiopulmonary exercise testing in COPD and cardiovascular diseases
Year: 2018
Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Pulmonary hypertension reduces exercise tolerance in COPD
Source: Annual Congress 2010 - Pulmonary circulation III
Year: 2010
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Impact of 3-months COVID-19 lockdown on exercise capacity in stable pulmonary arterial hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension
Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease
Year: 2011
Exercise training in pulmonary hypertension improves muscle efficiency and exercise capacity
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Effects of exercise training in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 669
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept